These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22894958)

  • 61. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
    DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
    Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand.
    Thomas R; Chansinghakul D; Limkittikul K; Gilbert PB; Hattasingh W; Moodie Z; Shangguan S; Frago C; Dulyachai W; Li SS; Jarman RG; Geretz A; Bouckenooghe A; Sabchareon A; Juraska M; Ehrenberg P; Michael NL; Bailleux F; Bryant C; Gurunathan S
    Hum Immunol; 2022 Jan; 83(1):53-60. PubMed ID: 34635391
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
    Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
    J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
    Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
    Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
    Yang Y; Meng Y; Halloran ME; Longini IM
    Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
    Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
    Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study.
    Ylade M; Crisostomo MV; Daag JV; Agrupis KA; Cuachin AM; Sy AK; Kim DR; Ahn HS; Escoto AC; Katzelnick LC; Adams C; White L; de Silva AM; Deen J; Lopez AL
    Lancet Infect Dis; 2024 Jul; 24(7):737-745. PubMed ID: 38527474
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.
    Bauer K; Esquilin IO; Cornier AS; Thomas SJ; Quintero Del Rio AI; Bertran-Pasarell J; Morales Ramirez JO; Diaz C; Carlo S; Eckels KH; Tournay E; Toussaint JF; De La Barrera R; Fernandez S; Lyons A; Sun W; Innis BL
    Am J Trop Med Hyg; 2015 Sep; 93(3):441-453. PubMed ID: 26175027
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dengue vaccine development by the year 2020: challenges and prospects.
    Wilder-Smith A
    Curr Opin Virol; 2020 Aug; 43():71-78. PubMed ID: 33086187
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Four-year safety follow-up of the tetravalent dengue vaccine CYD-TDV.
    Wilder-Smith A
    Clin Microbiol Infect; 2018 Jul; 24(7):680-681. PubMed ID: 29581052
    [No Abstract]   [Full Text] [Related]  

  • 72. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
    Morrison D; Legg TJ; Billings CW; Forrat R; Yoksan S; Lang J
    J Infect Dis; 2010 Feb; 201(3):370-7. PubMed ID: 20059357
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.
    Huang Y; Moodie Z; Juraska M; Fong Y; Carpp LN; Chambonneau L; Coronel DL; Dayan GH; DiazGranados CA; Gilbert PB
    Trans R Soc Trop Med Hyg; 2021 Jul; 115(7):750-763. PubMed ID: 33369671
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
    Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
    Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
    Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
    Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.
    Wilder-Smith A; Hombach J; Ferguson N; Selgelid M; O'Brien K; Vannice K; Barrett A; Ferdinand E; Flasche S; Guzman M; Novaes HM; Ng LC; Smith PG; Tharmaphornpilas P; Yoon IK; Cravioto A; Farrar J; Nolan TM
    Lancet Infect Dis; 2019 Jan; 19(1):e31-e38. PubMed ID: 30195995
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.